FBRX (Forte Biosciences) OCF Margin %: 0.00% (As of Mar. 2026)


FBRX Forte Biosciences Inc FBRX
35 GF Score
Price $21.03
! 2 Warning Signs
View Full Analysis

What is Forte Biosciences OCF Margin %?

Forte Biosciences FBRX +12.16% 35 OCF Margin % is 0.00% as of Mar. 2026. GuruFocus rates FBRX with a GF Score™ of 35/100. The stock has 2 warning signs investors should review. Among 959 Biotechnology companies, Forte Biosciences ranks worse than 104275.18% on this metric.

OCF Margin % is calculated as Cash Flow from Operations divided by its Revenue. Forte Biosciences's Cash Flow from Operations for the three months ended in Mar. 2026 was $-18.81 Mil. Forte Biosciences's Revenue for the three months ended in Mar. 2026 was $0.00 Mil. Therefore, Forte Biosciences's OCF Margin % for the quarter that ended in Mar. 2026 was 0.00%.

As of today, Forte Biosciences's current OCF Yield % is -13.78%.

The historical rank and industry rank for Forte Biosciences's OCF Margin % or its related term are showing as below:


FBRX's OCF Margin % is not ranked *
in the Biotechnology industry.
Industry Median: -66.52
* Ranked among companies with meaningful OCF Margin % only.

Forte Biosciences OCF Margin % Related Terms

Forte Biosciences OCF Margin % Historical Data

* Premium members only.

The historical data trend for Forte Biosciences's OCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Forte Biosciences OCF Margin % Chart

Forte Biosciences Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
OCF Margin %
Get a 7-Day Free Trial 0.00 0.00 0.00 0.00 0.00

Forte Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
OCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FBRX
35GF Score
Forte Biosciences Inc FBRX
OCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Forte Biosciences OCF Margin % Calculation

OCF Margin % is the ratio of Cash Flow from Operations divided by net sales or Revenue, usually presented in percent.

Forte Biosciences's OCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

OCF Margin=Cash Flow from Operations (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-50.882/0
= %

Forte Biosciences's OCF Margin for the quarter that ended in Mar. 2026 is calculated as

OCF Margin=Cash Flow from Operations (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-18.808/0
= %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about OCF Margin % →
What does a OCF Margin % of 0.00% mean?
Forte Biosciences (FBRX) has a OCF Margin % of 0.00% as of Mar. 2026. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Forte Biosciences and its competitors. According to the industry distribution chart, Forte Biosciences ranks #999999 out of 959 companies in the Biotechnology industry.
Is Forte Biosciences' OCF Margin % too high?
Forte Biosciences' current OCF Margin % is 0.00%. Based on the distribution chart, Forte Biosciences ranks #999999 out of 959 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Forte Biosciences has a GF Score™ of 35/100, reflecting its overall financial health beyond just this single metric.
How does Forte Biosciences' OCF Margin % compare to OABI and VNDA?
According to the Biotechnology industry distribution chart, Forte Biosciences ranks #999999 out of 959 companies for OCF Margin %. This places Forte Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good OCF Margin % for a Biotechnology company?
A good OCF Margin % depends on the Biotechnology industry context. However, OCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high OCF Margin % mean?
A high OCF Margin % can signal that a stock is expensive relative to its fundamentals. OCF Margin is the ratio of Cash Flow from Operations to Total Revenue. View historical data on Forte Biosciences and its competitors. Forte Biosciences's current OCF Margin % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Forte Biosciences stock overvalued right now?
Forte Biosciences (FBRX) has a current OCF Margin % of 0.00%. The current OCF Margin % is 0.00%. Forte Biosciences' overall GF Score™ is 35/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is OCF Margin % calculated?
OCF Margin % is calculated from a company's financial statements. For Forte Biosciences (FBRX), the current OCF Margin % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Forte Biosciences Business Description

Other Exchanges 37T:Germany
Address 3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247
Forte Biosciences Inc is a clinical-stage biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. The Company is also advancing clinical development of FB102 in patient-based trials for non-segmental vitiligo and alopecia areata.
35GF Score

Get the complete analysis for FBRX

OCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$21.03
Price